Previous 10 | Next 10 |
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point’s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to Receive $25 Million Upfront, with Up to Approximately $336 Million in Potential Milestone Payments and Royalties ...
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments. Ocumension Therapeutics inv...
Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each year Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China ...
Paratek Pharmaceuticals (PRTK) says it has entered into a $60M non-recourse loan agreement with an affiliate of R-Bridge Healthcare Investment Advisory for 12 years; The proceeds will be used for repayment of Hercules senior secured debt.Paratek says this non-recourse loan will be repaid...
DXY.cn, a China healthcare platform, raised $500 million in an E round. Zai Lab in-licensed China rights to a next-gen EGFR inhibitor aimed at cells expressing mutant EGFR variants from Boston's Cullinan Oncology in an agreement worth up to $233 million. Hutchison China MediTech a...
SHANGHAI and SAN FRANCISCO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, wil...
SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA® has been included in the updated National Reimbursement Drug List (NRDL) released by China...
Zai Lab (ZLAB) and Cullinan Oncology (CGEM) entered into an exclusive license agreement for the development, manufacturing and commercialization of CLN-081 in Greater China.Cullinan Oncology is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology ...
- Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties - Zai Lab to join ongoing global trial for CLN-081 SHANGHAI and SAN FRANCISCO and CAMBR...
BAMCO’s 13F portfolio value increased from $27.66B to $32.58B this quarter. Ron Baron decreased Tesla while increasing ZoomInfo Tech during the quarter. Their top five positions are at ~25% of the overall portfolio. For further details see: Tracking Ron Baron's BA...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...